[Hplusroadmap] Fwd: [tt] External artificial liver

[Bryan Bishop]

----------  Forwarded Message  ----------

Subject: [tt] External artificial liver
Date: Monday 11 February 2008
From: "Hughes, James J." <James.Hughes at trincoll.edu>
To: tt at postbiota.org

 
http://hepalife.com/press_releases/20080211-1.html.php

HepaLife's Bioartificial Liver Dramatically Reduces Toxic Marker for
Acute Liver Failure

Boston, MA - February 11, 2008 - HepaLife Technologies, Inc. (OTCBB:
HPLF) (FWB: HL1) (WKN: 500625) today announced important, positive
results from new in-vitro studies in which the Company's patented
PICM-19 liver stem cells were placed inside its proprietary
bioartificial liver device and were able to successfully and quickly
remove high levels of toxic ammonia within a very short period of time.

"Acute liver failure leads to increased blood ammonia levels. The
ammonia is taken up by the brain and can cause brain damage, coma, and
even death. Reducing the present high levels of ammonia in those
patients as soon as possible is a key target for successful patient
treatment and patient recovery," explained Stephen R. Ash, MD., a
HepaLife Scientific Advisory Board Member, Physician at Clarian-Arnett
Health and Medical Director at Wellbound, Inc. of Lafayette, IN.

When challenged with high amounts of toxic ammonia, present in patients
with acute liver failure, HepaLife's bioartificial liver reduced ammonia
levels by 75% within less than 24 hours. Published in-vivo clinical data
of other systems utilizing liver cells other than HepaLife's patented
PICM-19, have only reported ammonia reduction levels between 0 to 44%.

Mr. Frank Menzler, President and CEO of HepaLife Technologies, Inc.,
explained, "These test findings are especially important because ammonia
is a highly dangerous by-product in patients with acute liver failure,
and researchers have long considered the efficient removal or reduction
of toxic ammonia an important requirement for an artificial liver device
intended for human use. 

"Our bioartificial liver technology not only removes this ammonia, but
importantly, is capable of producing high levels of urea, a feature
regarded vital in the biochemical improvement of acute liver failure
patients undergoing clinical treatment by way an artificial liver.  Our
bioartificial liver achieves this essential outcome by making use of
HepaLife's patented PICM-19 cells, the only cell line of its kind able
to produce such high levels of urea."


Positive Outcomes from Tests of HepaLife's Bioartificial Liver
In recent tests, HepaLife's bioartificial liver reduced levels of toxic
ammonia by 75% in fewer than 24 hours, a feature considered necessary to
the successful treatment of acute liver failure using an artificial
liver.

According to researchers, biochemical improvement as a result of an
artificial liver device treatment in clinical application is judged not
only by the elimination of ammonia, but also by the production of urea.
Importantly, HepaLife's PICM-19 cells synthesized 80% of the ammonia
present into urea, the normal pathway of ammonia reduction of the human
liver. HepaLife's PICM-19 cell line is the only known liver stem cell
line of its kind with this ability to produce substantial amount of
urea.

During these same tests HepaLife's PICM-19 liver stem cells inside the
Company's bioartificial liver maintained differentiated hepatic (liver)
function, showing typical hepatocyte morphology -- the characteristics
representative of human liver cells -- including cell features such as
intercellular canaliculi, extensive Golgi apparatus, endoplasmic
reticulum, peroxisomes and mitochondria.

"The performance of our bioartificial liver device is exciting. The rate
of ammonia reduction achieved mainly via the natural urea cycle is an
important step towards successful clinical application," continued Mr.
Menzler.  "Furthermore, the ability of our cells to produce substantial
amounts of urea while maintaining liver-like function, and preserving
liver cell-like characteristics, all clearly establish the superior
performance of our PICM-19 cell line inside our bioartificial liver."

Intended for the treatment of liver failure, the HepaLife(tm)
Bioartificial Liver device consists of three basic components: (1) a
plasma filter, separating the patients blood into blood plasma and blood
cells; (2) the bioreactor, a unit filled with the patented PICM-19 liver
stem cell line  which biologically mimics the liver's function; and (3),
the HepaDrive(tm), a perfusion system for pumping the patient's plasma
through the bioreactor while controlling gas supply and temperature for
best possible performance of the cells.

Incorporating the PICM-19 cell line, HepaLife is developing the
first-of-its-kind bioartificial liver. HepaLife's bioartificial liver
currently under development, is designed to operate outside the
patient's body. The bioartificial liver is envisioned to mimic important
functions of the human liver by circulating the patient's blood inside
the device, where it is exposed to HepaLife's patented PICM-19 liver
stem cells, thus processing the patient's blood-plasma by removing
toxins, enhancing metabolic function, and ultimately, imitating the
liver's natural function.

ABOUT HEPALIFE TECHNOLOGIES, INC.

Based in Boston, Massachusetts, HepaLife Technologies, Inc. (OTCBB:
HPLF) (FWB: HL1) (WKN: 500625) is a developer of cell-based medical
technologies addressing prevalent human health concerns.

Current cell-based technologies under development by HepaLife include 1)
the first-of-its-kind artificial liver device, 2) proprietary in-vitro
toxicology and pre-clinical drug testing platforms, and 3) novel
cell-culture based vaccine production methods for the manufacture of
vaccines against H5N1 avian influenza and other viruses.

For additional information, please visit www.hepalife.com.

To receive future press releases via email, please visit:
http://www.hepalife.com/investor_alerts.php


_______________________________________________
tt mailing list
tt at postbiota.org
http://postbiota.org/mailman/listinfo/tt

-------------------------------------------------------
________________________________________
Bryan Bishop
http://heybryan.org/